The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial

What Was Tested

Researchers studied Abaloparatide in this randomized controlled trial publication.

The primary endpoint was change from baseline in lumbar spine BMD.

Key secondary endpoints included BMD change from baseline at the total hip and femoral neck.

Who Took Part

The abstract describes 228 men taking part.

By PubMed's age tags, the people studied were older adults, men only.

A total of 228 men were randomized (abaloparatide, n = 149; placebo, n = 79).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.

Neither the men nor the staff measuring them knew who was on Abaloparatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Abaloparatide group a baseline to be compared against.

What Was Measured

The primary endpoint was change from baseline in lumbar spine BMD.

Key secondary endpoints included BMD change from baseline at the total hip and femoral neck.

PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Femur Neck, Osteoporosis and Parathyroid Hormone-Related Protein.

The authors tagged it with the keywords ABALOPARATIDE, BONE MINERAL DENSITY, FRACTURE and MEN.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide in 228 men.

The publication is from 2022 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Abaloparatide compound page, all human trials.